Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
RL Yauch, T Januario, DA Eberhard, G Cavet… - Clinical Cancer …, 2005 - AACR
… detection of erlotinib-sensitive NSCLC tumor cells with … erlotinib-mediated growth inhibition
in NSCLC tumor cell lines but may also serve as a potential biomarker in predicting erlotinib …
in NSCLC tumor cell lines but may also serve as a potential biomarker in predicting erlotinib …
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non–small cell lung cancer cells
T Li, YH Ling, ID Goldman, R Perez-Soler - Clinical cancer research, 2007 - AACR
… cells to erlotinib followed by pemetrexed was mostly antagonistic in erlotinib-sensitive cells
and additive at best in erlotinib-… erlotinib-sensitive cells and an additive interaction in erlotinib-…
and additive at best in erlotinib-… erlotinib-sensitive cells and an additive interaction in erlotinib-…
Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second …
TM Chin, MP Quinlan, A Singh, LV Sequist… - Clinical cancer …, 2008 - AACR
… cell culture models, where we showed that whereas the IC 50 of erlotinib sensitivity in untreated
versus cisplatin-treated cells … of erlotinib is substantially increased in the cisplatin-treated …
versus cisplatin-treated cells … of erlotinib is substantially increased in the cisplatin-treated …
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
Q Dai, YH Ling, M Lia, YY Zou, G Kroog, KK Iwata… - Clinical Cancer …, 2005 - AACR
… In phase II clinical studies, oral erlotinib monotherapy has shown antitumor activity in
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian cancer …
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian cancer …
Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer
Y Li, S Lam, JC Mak, C Zheng, JC Ho - Lung cancer, 2013 - Elsevier
… erlotinib sensitivity in sensitive cells. Similarly, silencing of Atg5 or Beclin-1 significantly
increased sensitivity to erlotinib in both sensitive cell … H1975 cell lines upon erlotinib exposure. …
increased sensitivity to erlotinib in both sensitive cell … H1975 cell lines upon erlotinib exposure. …
Sensitization of EGFR wild-type non–small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib
J Raimbourg, MP Joalland, M Cabart, L de Plater… - Molecular Cancer …, 2017 - AACR
… High-dose cisplatin treatment was shown to induce EGFR activation in lung cancer cell
lines (14). … upon the surviving cells sensitivity to erlotinib, either in wild-type or mutated-EGFR …
lines (14). … upon the surviving cells sensitivity to erlotinib, either in wild-type or mutated-EGFR …
[HTML][HTML] YAP promotes erlotinib resistance in human non-small cell lung cancer cells
PC Hsu, B You, YL Yang, WQ Zhang, YC Wang, Z Xu… - Oncotarget, 2016 - ncbi.nlm.nih.gov
… , invasion and tumor sphere formation abilities in H1975 cells. … erlotinib resistance in the
erlotinib-sensitive NSCLC cell line … sensitivity of erlotinib-resistant NSCLC cell line H1975 to …
erlotinib-sensitive NSCLC cell line … sensitivity of erlotinib-resistant NSCLC cell line H1975 to …
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET
G Abourbeh, B Itamar, O Salnikov, S Beltsov… - EJNMMI research, 2015 - Springer
… of [ 11 C]erlotinib in differentiating erlotinib-sensitive tumors from erlotinib-insensitive or
erlotinib-resistant ones. To this end, four different human NSCLC cell lines were employed, two …
erlotinib-resistant ones. To this end, four different human NSCLC cell lines were employed, two …
[HTML][HTML] Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib
K Suda, K Tomizawa, M Fujii, H Murakami… - Journal of thoracic …, 2011 - Elsevier
… We developed resistant cells (HCC4006ER) from erlotinib-sensitive HCC4006 cells
harboring an EGFR deletion mutation by chronic exposure to increasing concentrations of …
harboring an EGFR deletion mutation by chronic exposure to increasing concentrations of …
LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells
YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2016 - nature.com
… cells might confer sensitivity to erlotinib through inhibition of mTOR signaling. As shown in
Figure 5c, erlotinib … Calu-6 cells after 24 h, but shLKB1 cells exhibited complete disruption of …
Figure 5c, erlotinib … Calu-6 cells after 24 h, but shLKB1 cells exhibited complete disruption of …
相关搜索
- non-small cell lung cancer
- cell lung cancer erlotinib in patients
- small cell lung cancer randomized phase
- cell lung cancer growth factor
- erlotinib pet cell lung carcinoma tumors
- cell lung cancer cells drug sensitivity
- energetic stress small cell lung cancers
- small cell lung cancer marker analyses
- cell lung cancer treatment with erlotinib
- cell lung cancer cells wild type
- cell lung cancer lkb1 inactivation
- small cell lung cancer prior chemotherapy
- cell lung cancer cells cytotoxic synergism
- small cell lung cancer safety relationship
- small cell lung cancer pharmacodynamic study
- small cell lung cancer clinical pharmacokinetics